News | May 21, 2010

First Successful Deployment of New Transcatheter Mitral Valve Disclosed

May 21, 2010 – The first successful transcatheter mitral valve implantation (TMVI) for a new mitral valve technology will be highlighted at the EuroPCR 2010 scientific meeting in Paris. A proprietary transcatheter delivery system was used to successfully deliver the valve in the porcine model.

Arshad Quadri, M.D., co-founder, chairman and chief medical officer of Cardiaq Valve Technologies (CVT), will present information about the new self-conforming and self-anchoring valve Tuesday, May 25. The presentation will report six major outcomes of an acute in vivo study of the TMVI system:

• Accurate positioning of the implanted valve relative to the mitral valve annulus
• Secure anchoring of the implanted valve to the mitral anatomy without relying on radial force
• Preservation of the subvalvular apparatus
• Conformance of the implanted valve to the mitral annulus to prevent paravalvular leaks
• Confirmation of a clear, unobstructed left ventricular outflow tract (LVOT)
• The successful delivery and deployment of the implant through an antegrade, transvenous, transseptal, catheter-based approach

Other companies have published results for minimally invasive, transapical approaches to mitral valve replacement. However, CVT believes this is the first time anyone has successfully deployed a mitral valve through a transvenous, transseptal, catheter-based approach.

“Given the enormous unmet clinical need for the overwhelming majority of patients who suffer from mitral regurgitation (MR), we are extremely pleased by this significant milestone,” Quadri said. “The vast majority of MR patients suffer from functional MR and many are too sick to undergo heart valve surgery. In addition, surgical repair is largely ineffective with these patients, as the recurrent rate of MR after repair is about 20 percent. With CVT’s TMVI approach, it appears that easy access along with precise placement may permit a truly interventional or nonsurgical procedure to replace a mitral valve.”

The CVT procedure is designed to be performed in a cardiac catheterization laboratory similar to angioplasty or stenting, resulting in less trauma to the patient and substantial cost-savings to the healthcare system.

For more information:

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init